WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
Fax: +47 21 07 81 46
E-mail:
 
Copyright/Disclaimer

New DDDs

Overview of new DDDs decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the DDDs from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new DDD will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

ATC codeATC level name (INN/generic name)DDDUnit =100Adm.routeDeadline for objection to temporary DDDs 1) Implementation in ATC/DDD index if no objection is received
A10BH04alogliptin25mgO01.09.20152016
A10BX11canagliflozin0.2gOFinal2016
A10BX12empagliflozin17.5mgO01.09.20152016
A10BX13albiglutide5.7mgPFinal2016
A10BX14dulaglutide0.16mgP01.09.20152016
A16AX08teduglutide5mgP01.09.20152016
A16AX10eliglustat0.168gO01.09.20152016
C02KX05riociguat4.5mgOFinal2016
C09CA09azilsartan medoxomil40mgOFinal2016
C10AX12lomitapide40mgOFinal2016
G02AD06misoprostol0.2mgV 2)Final2016
J01XB01colistin3MUInhal. powder01.09.20152016
J05AE14simeprevir0.15gOFinal2016
J05AX14daclatasvir60mgOFinal2016
J05AX16dasabuvir0.5gO01.09.20152016
L02BX01abarelix3.6mgPFinal2016
L03AB13peginterferon beta-1a8.9mcgPFinal2016
L04AA29tofacitinib10mgO01.09.20152016
L04AA33vedolizumab5.4mgPFinal2016
L04AC11siltuximab37mgPFinal2016
N05AH01loxapine9.1mg 3)inhal powderFinal2016
N05AX12aripiprazole13.3mgP depotFinal2016
N06BA11dexmethylphenidate15mgOFinal2016
N06BA13armodafinil0.15gO01.09.20152016
P01BE03artesunate0.28gP01.09.20152016
R03AC19olodaterol5mcginhal solFinal2016
R03BB07umeclidinium bromide55mcg 4)Inhal. powder01.09.20152016
R03CC13clenbuterol40mcgO01.09.20152016
V03AE05sucroferric oxyhydroxide1.5gOFinal2016
V03AX03cobicistat0.15gOFinal2016
1) Final: indicates that the date for objection has expired
2) vaginal insert, refers to the content of one vaginal insert
3) delivered dose
4) Refers to umeclidinium, delivered dose

Last updated: 2015-06-10